Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inflammatory Responses of Astrocytes Are Independent from Lipocalin 2.
Gasterich N, Wetz S, Tillmann S, Fein L, Seifert A, Slowik A, Weiskirchen R, Zendedel A, Ludwig A, Koschmieder S, Beyer C, Clarner T. Gasterich N, et al. Among authors: koschmieder s. J Mol Neurosci. 2021 May;71(5):933-942. doi: 10.1007/s12031-020-01712-7. Epub 2020 Sep 21. J Mol Neurosci. 2021. PMID: 32959226
The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR-ABL- and JAK2V617F-Positive MPN.
Tillmann S, Olschok K, Schröder SK, Bütow M, Baumeister J, Kalmer M, Preußger V, Weinbergerova B, Kricheldorf K, Mayer J, Kubesova B, Racil Z, Wessiepe M, Eschweiler J, Isfort S, Brümmendorf TH, Becker W, Schemionek M, Weiskirchen R, Koschmieder S, Chatain N. Tillmann S, et al. Among authors: koschmieder s. Cancers (Basel). 2021 Aug 21;13(16):4210. doi: 10.3390/cancers13164210. Cancers (Basel). 2021. PMID: 34439364 Free PMC article.
A 'telomere-associated secretory phenotype' cooperates with BCR-ABL to drive malignant proliferation of leukemic cells.
Braig M, Pällmann N, Preukschas M, Steinemann D, Hofmann W, Gompf A, Streichert T, Braunschweig T, Copland M, Rudolph KL, Bokemeyer C, Koschmieder S, Schuppert A, Balabanov S, Brümmendorf TH. Braig M, et al. Among authors: koschmieder s. Leukemia. 2014 Oct;28(10):2028-39. doi: 10.1038/leu.2014.95. Epub 2014 Mar 7. Leukemia. 2014. PMID: 24603533
JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation.
Czech J, Cordua S, Weinbergerova B, Baumeister J, Crepcia A, Han L, Maié T, Costa IG, Denecke B, Maurer A, Schubert C, Feldberg K, Gezer D, Brümmendorf TH, Müller-Newen G, Mayer J, Racil Z, Kubesova B, Knudsen T, Sørensen AL, Holmström M, Kjær L, Skov V, Larsen TS, Hasselbalch HC, Chatain N, Koschmieder S. Czech J, et al. Among authors: koschmieder s. Leukemia. 2019 Apr;33(4):995-1010. doi: 10.1038/s41375-018-0295-6. Epub 2018 Nov 23. Leukemia. 2019. PMID: 30470838
JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms.
Rao TN, Hansen N, Hilfiker J, Rai S, Majewska JM, Leković D, Gezer D, Andina N, Galli S, Cassel T, Geier F, Delezie J, Nienhold R, Hao-Shen H, Beisel C, Di Palma S, Dimeloe S, Trebicka J, Wolf D, Gassmann M, Fan TW, Lane AN, Handschin C, Dirnhofer S, Kröger N, Hess C, Radimerski T, Koschmieder S, Čokić VP, Skoda RC. Rao TN, et al. Among authors: koschmieder s. Blood. 2019 Nov 21;134(21):1832-1846. doi: 10.1182/blood.2019000162. Blood. 2019. PMID: 31511238 Free PMC article.
Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms.
Baumeister J, Chatain N, Hubrich A, Maié T, Costa IG, Denecke B, Han L, Küstermann C, Sontag S, Seré K, Strathmann K, Zenke M, Schuppert A, Brümmendorf TH, Kranc KR, Koschmieder S, Gezer D. Baumeister J, et al. Among authors: koschmieder s. Leukemia. 2020 Apr;34(4):1062-1074. doi: 10.1038/s41375-019-0629-z. Epub 2019 Nov 14. Leukemia. 2020. PMID: 31728053
226 results